ELCC 2025 | Professor Rui Ma on the Final OS Results from the MARIPOSA Study

ELCC 2025 | Professor Rui Ma on the Final OS Results from the MARIPOSA Study

The 2025 European Lung Cancer Congress (ELCC) officially opened on March 26 in Paris, France. On the very first day, during the Proffered Paper Session 1, the highly anticipated final overall survival (OS) results from the MARIPOSA study (Abstract 4O) were presented.Oncology Frontier invited Professor Rui Ma of Liaoning Cancer Hospital to provide an in-depth expert analysis of the updated data and its implications for clinical practice.
ELCC 2025 | Professor Gen Lin: Promising Results for Osimertinib Plus Dato-DXd in TKI-Resistant NSCLC from the ORCHARD Study

ELCC 2025 | Professor Gen Lin: Promising Results for Osimertinib Plus Dato-DXd in TKI-Resistant NSCLC from the ORCHARD Study

At the 2025 European Lung Cancer Congress (ELCC), new data from the ORCHARD study were presented, highlighting the potential of osimertinib in combination with Dato-DXd as a post-progression strategy following first-line osimertinib treatment in patients with EGFR-mutant non-small cell lung cancer (NSCLC). This marks the first public release of efficacy and safety findings for this combination in the treatment of EGFR-TKI resistant NSCLC.
ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition

ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition

The recently concluded 2025 European Lung Cancer Congress (ELCC) spotlighted several key clinical topics and unveiled new research with strong translational potential. Oncology Frontier invited Professor Wei Zhang of Shanghai Chest Hospital, Shanghai Jiao Tong University for an in-depth interview, where she shared expert insights on the congress's most impactful themes and dissected the scientific highlights shaping the future of lung cancer treatment.
Blood Science Update|In Vitro Erythropoiesis: The Emerging Potential of Induced Pluripotent Stem Cells (iPSCs)

Blood Science Update|In Vitro Erythropoiesis: The Emerging Potential of Induced Pluripotent Stem Cells (iPSCs)

Despite over 100 million units of blood being donated annually, supply remains insufficient, particularly for patients with chronic conditions or in crisis settings. Alloimmunization and blood group incompatibilities further constrain transfusion efficacy. In response, researchers are exploring the use of induced pluripotent stem cells (iPSCs) to generate red blood cells (RBCs) in vitro as a reliable and potentially limitless source of transfusable cells. The journal Blood Science (2025) presents a comprehensive review of the current progress, challenges, and future directions of iPSC-derived erythropoiesis.